Close Menu

NEW YORK – Glycoproteomics diagnostic firm InterVenn BioSciences is developing a test for the early detection of colorectal cancer.

According to Klaus Lindpaintner, the company's chief scientific and medical officer, a pilot study found the test was able to detect colorectal cancer with 98 percent sensitivity and 91 percent specificity and advanced adenomas with 98 percent sensitivity and 85 percent specificity.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.